What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Schizophrenia
- Psychiatry
His main research concerns Schizophrenia, Psychiatry, Antipsychotic, Olanzapine and Internal medicine.
His Schizophrenia research integrates issues from Haloperidol, Psychosis, Prospective cohort study and Nicotine.
Joseph Patrick McEvoy interconnects Emotionality, Clinical trial and Clinical psychology in the investigation of issues within Psychiatry.
Joseph Patrick McEvoy has included themes like Risperidone, Anesthesia and Atypical antipsychotic in his Olanzapine study.
His Risperidone research is multidisciplinary, incorporating elements of Quetiapine, Schizoaffective disorder and Randomized controlled trial.
The concepts of his Quetiapine study are interwoven with issues in Discontinuation and Perphenazine.
His most cited work include:
- Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia (4568 citations)
- Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia (4568 citations)
- Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. (935 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Psychiatry, Schizophrenia, Antipsychotic, Internal medicine and Olanzapine.
Joseph Patrick McEvoy usually deals with Psychiatry and limits it to topics linked to Clinical psychology and Cognition, Neuropsychology and Mental health.
His biological study spans a wide range of topics, including Haloperidol, Anesthesia and Psychosis.
His Antipsychotic study combines topics in areas such as Tardive dyskinesia, Discontinuation and Pharmacology, Perphenazine.
Joseph Patrick McEvoy combines subjects such as Placebo and Endocrinology with his study of Internal medicine.
Joseph Patrick McEvoy focuses mostly in the field of Olanzapine, narrowing it down to matters related to Risperidone and, in some cases, Aripiprazole.
He most often published in these fields:
- Psychiatry (56.73%)
- Schizophrenia (43.55%)
- Antipsychotic (33.24%)
What were the highlights of his more recent work (between 2013-2021)?
- Psychiatry (56.73%)
- Schizophrenia (43.55%)
- Internal medicine (32.38%)
In recent papers he was focusing on the following fields of study:
Joseph Patrick McEvoy mainly focuses on Psychiatry, Schizophrenia, Internal medicine, Tardive dyskinesia and Antipsychotic.
His Schizophrenia research focuses on Clozapine in particular.
His work carried out in the field of Internal medicine brings together such families of science as Oncology and Positive and Negative Syndrome Scale.
Akathisia is the focus of his Antipsychotic research.
Joseph Patrick McEvoy works mostly in the field of Schizophrenia, limiting it down to concerns involving Antipsychotic Medications and, occasionally, Olanzapine.
His studies in Randomized controlled trial integrate themes in fields like Psychological intervention, Young adult, Quetiapine, Ziprasidone and Aerobic exercise.
Between 2013 and 2021, his most popular works were:
- Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. (90 citations)
- Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. (83 citations)
- A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns. (40 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Schizophrenia
- Psychiatry
Joseph Patrick McEvoy mostly deals with Internal medicine, Antipsychotic, Schizophrenia, Psychiatry and Randomized controlled trial.
His studies deal with areas such as Schizoaffective disorder, Olanzapine and Discontinuation as well as Antipsychotic.
His Olanzapine study combines topics from a wide range of disciplines, such as Quetiapine, Risperidone and Perphenazine.
His Clozapine study in the realm of Schizophrenia interacts with subjects such as Adiponectin.
His study in the field of Positive and Negative Syndrome Scale, Major depressive disorder and Bipolar disorder also crosses realms of Patient-reported outcome.
As part of one scientific family, Joseph Patrick McEvoy deals mainly with the area of Randomized controlled trial, narrowing it down to issues related to the Clinical trial, and often Relapse prevention, Psychosis, Sexual dysfunction and Acute Psychotic Episode.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
